UPDATE: Goldman Sachs Starts Editas Medicine (EDIT) at Sell, Cautious on Lead Drugs
Tweet Send to a Friend
(Updated - April 16, 2021 4:14 AM EDT)
Goldman Sachs analyst Madhu Kumar initiates coverage on Editas Medicine (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Goldman Sachs analyst Madhu Kumar initiates coverage on Editas Medicine (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE